Advancing Hypoimmune iPSC‑Derived Dopaminergic Progenitors (NCR201) Toward Clinical Translation in Parkinson’s Disease

• Sharing early safety and tolerability insights from Nuwacell’s NCR201 Phase I/II trial
• Highlighting long-term efficacy and biological activity from investigator-initiated trials
• Building scalable CMC foundations aligned with NCR201’s accelerated development route

Speakers:

Luyan Jiao

Vice President - New Drug Development

Nuwacell